Table 2.
The core references of targeted therapy resistance
| Cells | Cancer | Drug | Article track |
|---|---|---|---|
| Tumor associated macrophages | Breast cancer | Lapatinib | 10.1016/j.bbamcr.2021.118995 |
| Tumor-associated macrophages | Multiple myeloma | Ferric ammonium citrate | 10.1016/j.redox.2020.101611 |
| Tumor-associated macrophages | Lung cancer | Gefitinib | 10.3892/ol.2022.13476 |
| Tumor-associated macrophages | Ovarian cancer | PARP inhibition | 10.1136/jitc-2022-005627 |
| Tumor-associated macrophages | Lung cancer | Gefitinib | 10.1016/j.canlet.2023.216205 |
| Myeloid-derived suppressor cells | Lung cancer | Osimertinib | 10.1111/1759-7714.14929 |
| Neutrophils | Breast cancer | Anti-VEGFR2 therapy | 10.3389/fimmu.2021.699478 |
| NK cells | Breast cancer | Trastuzumab | 10.1038/s41392-021-00629-w |
| Aged fibroblasts | Melanoma | Targeted therapy | https://doi.org/10.1158/2159-8290.CD-20-0329 |
| Tumor-associated fibroblasts | Ovarian cancer | Bepotastine | https://doi.org/10.1158/1535-7163.MCT-22-0396 |
| Tumor-associated fibroblasts | Neuroendocrine cancer | Everolimus | https://doi.org/10.1159/000528539 |
| Tumor-associated fibroblasts | Lung cancer | EGFR TKIs | 10.1186/s12885-022-09877-7 |
| Tumor-associated fibroblasts | Gastric cancer | Anlotinib | 10.1016/j.redox.2021.102076 |
| Tumor-associated fibroblasts | Colorectal cancer | BET inhibitor | 10.1038/s41467-021-24687-4 |
| Tumor-associated fibroblasts | Head and neck cancer | Cetuximab | 10.3390/cancers12020339 |
| Tumor-associated fibroblasts | Breast cancer | HER2 kinase therapy | 10.1073/pnas.2000648117 |
| Tumor-associated fibroblasts and mesenchymal stem cells | Breast cancer | Lapatinib | 10.1038/s41388-021-01906-2 |
| Tumor-associated fibroblasts | Chronic myeloid leukemia | Dasatinib | 10.3390/life13020259 |
| Mesenchymal stem cells | Multiple myeloma | Bortezomib | 10.17305/bjbms.2019.4344 |
| Mesenchymal stem cells | Gastric cancer | Tyrosine kinase inhibitors | 10.1186/s12967-023-04063-0 |
| Bone marrow stromal cells | Chronic myeloid leukemia | Imatinib mesylate | 10.1097/CM9.0000000000002554 |
| Bone marrow stromal cells | Multiple myeloma | Bortezomib | https://doi.org/10.1158/1541-7786.MCR-21-0941 |
| Bone marrow-derived mesenchymal stem cells | Lung cancer | Erlotinib | 10.1080/15384047.2019.1665952 |
| Bone marrow stromal cells | Multiple myeloma | Bortezomib | 10.1158/0008-5472.CAN-23-0189 |
| Endothelial cells | Hepatocellular cancer | Sorafenib | 10.1155/2022/2543220 |
| Endothelial cells | Glioma | Anti-VEGF treatment | 10.1016/j.canlet.2017.05.030 |
| Pericytes | Glioblastoma | BRAFV600E kinase inhibitor | 10.1002/advs.202201888 |